John Hussman's NBIX Position Overview
John Hussman (via Hussman Strategic Advisors, Inc.) currently holds 21,000 shares of Neurocrine Biosciences, Inc. (NBIX) worth $2.98 M, representing 0.72% of the portfolio. First purchased in 2018-Q4, this long-term strategic position has been held for 26 quarters.
Based on 13F filings, John Hussman has maintained a strategic position in NBIX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 21,000 shares. Largest reduction occurred in Q2 2025, reducing 25,200 shares.
Analysis based on 13F filings available since 2013 Q2
John Hussman's Neurocrine Biosciences (NBIX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Neurocrine Biosciences (NBIX) Trades by John Hussman
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2025 | +21,000 | New Buy | 21,000 | $140.38 |
| Q2 2025 | -25,200 | Sold Out | 0 | $0.00 |
| Q1 2025 | +16,800 | Add 200.00% | 25,200 | $110.60 |
| Q4 2024 | -23,100 | Reduce 73.33% | 8,400 | $136.50 |
| Q3 2024 | +6,300 | Add 25.00% | 31,500 | $115.22 |
| Q2 2024 | +14,700 | Add 140.00% | 25,200 | $137.67 |
| Q4 2023 | -17,900 | Reduce 63.03% | 10,500 | $131.76 |
| Q3 2023 | -8,000 | Reduce 21.98% | 28,400 | $112.50 |
| Q2 2023 | -10,100 | Reduce 21.72% | 36,400 | $94.30 |
| Q1 2023 | +20,500 | Add 78.85% | 46,500 | $101.22 |
| Q4 2022 | -5,200 | Reduce 16.67% | 26,000 | $119.44 |
| Q1 2022 | +20,800 | Add 200.00% | 31,200 | $93.75 |
| Q4 2021 | -5,100 | Reduce 32.90% | 10,400 | $85.19 |
| Q2 2021 | +15,500 | New Buy | 15,500 | $97.29 |
| Q4 2020 | -10,000 | Sold Out | 0 | $0.00 |
| Q2 2020 | -5,000 | Reduce 33.33% | 10,000 | $122.00 |
| Q1 2020 | +15,000 | New Buy | 15,000 | $86.53 |
| Q2 2019 | -10,000 | Sold Out | 0 | $0.00 |
| Q4 2018 | +10,000 | New Buy | 10,000 | $71.40 |
John Hussman's Neurocrine Biosciences Investment FAQs
John Hussman first purchased Neurocrine Biosciences, Inc. (NBIX) in Q4 2018, acquiring 10,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
John Hussman has held Neurocrine Biosciences, Inc. (NBIX) for 26 quarters since Q4 2018.
John Hussman's largest addition to Neurocrine Biosciences, Inc. (NBIX) was in Q3 2025, adding 21,000 shares worth $2.95 M.
According to the latest 13F filing for Q4 2025, John Hussman's firm, Hussman Strategic Advisors, Inc., owns 21,000 shares of Neurocrine Biosciences, Inc. (NBIX), valued at approximately $2.98 M.
As of the Q4 2025 filing, Neurocrine Biosciences, Inc. (NBIX) represents approximately 0.72% of John Hussman's publicly disclosed stock portfolio, making it one of their key holdings.
John Hussman's peak holding in Neurocrine Biosciences, Inc. (NBIX) was 46,500 shares, as reported at the end of Q1 2023.